登录 | 注册    关注公众号  
微信公众号
搜索
 > 【TACI】

TACI信息

英文名称:Tumor necrosis factor receptor superfamily member 13B
中文名称:肿瘤坏死因子受体13B基因
靶点别称:Transmembrane activator and CAML interactor,CD267,TACI
上市药物数量:0
临床药物数量:1
最高研发阶段:临床一期

TACI分子别名

CD267,TACI,TNFRSF13B

TACI分子背景

Transmembrane activator and CAML interactor (TACI), also known as tumor necrosis factor receptor superfamily member 13B (TNFRSF13B). It was originally discovered because of its ability to interact with calcium-modulator and cyclophilin ligand (CAML). TACI was later found to play a crucial role in humoral immunity by interacting with two members of the TNF family: BAFF and APRIL.
The present study demonstrated that, in NSCLC, a proliferation-inducing ligand (APRIL), B-cell maturation antigen (BCMA)and transmembrane activator and CAML interactor (TACI) proteins are abnormally expressed by immunohistochemistry, reverse transcription-quantitative polymerase chain reaction and western blotting. In addition, the expression of APRIL, BCMA and TACI were observed to be involved in extracellular signal-regulated kinase (ERK)1/2 activation in A549 cells.

TACI临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验

消息提示

请输入您的联系方式,再点击提交!

确定